anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: To compare hidden blood loss (HBL) of minimally invasive transforaminal lumbar interbody fusion (Mis-TLIF) of lumbar degenerative diseases in patients with or without osteoporosis (OP) and identify the risk factors for HBL with OP.
METHODS: The data from 156 patients with lumbar degenerative diseases, who underwent Mis-TLIF between January 2018 and December 2021, were retrospectively analyzed. The patients were divided into the Osteoporosis and Non-osteoporosis groups. We recorded demographic characteristics and blood-related parameters in each group. Blood loss was measured by quantifying visible blood loss and calculating HBL using preoperative hematocrit (Hctpre) and postoperative hematocrit (Hctpost). Pearson or Spearman correlation analysis was used to investigate the association between OP patient's characteristics and HBL. Multivariate linear regression analysis was used to confirm independent risk factors of HBL in patients with OP.
RESULTS: The mean HBL of the Osteoporosis and Non-osteoporosis groups was 608.27 ± 175.23 and 173.04 ± 67.55 ml, respectively. There were significant differences in age, BMI, subcutaneous fat thickness, muscle thickness, Hctpost, average hematocrit of preoperative and postoperative (Hctave), visible blood loss, HBL and volume of allogeneic blood transfusions between the two groups (P < 0.05). Multivariate linear regression analysis showed that Hctpost, T-score, use of tranexamic acid (TXA) and preoperative regular anti-osteoporosis treatment were independent risk factors for HBL in patients with OP.
CONCLUSION: There was significant perioperative HBL in patients with OP. Hctpost, T-score, use of TXA and preoperative regular anti-osteoporosis treatment were independent risk factors for HBL in patients with OP. More attention should be paid to the perioperative period to ensure the safety of patients with OP.
Participants in the TOT (task-oriented training) group will receive task-oriented training as home program. They will undergo a 40-minute home-based training program once a day, 5 days a week for 4 weeks.
PURPOSE:To obtain a material capable of providing a high relative density at a relatively low calcination temp. and having improved strength by molding a powdery material based on calcium phosphate and calcining preliminarily under specified conditions, then calcining finally in the air or in inactive atmosphere. CONSTITUTION:After forming a powdery material basing on calcium phosphate, for formed body is calcined preliminarily in vacuum or under reduced pressure until its relative density attains >=95%. Then, the preliminarily formed body is calcined further and finally in the air or in inactive atmosphere. Suitable powdery material basing on calcium phosphate is Ca10(PO4)6(OH)2, Ca3(PO4)2, Ca2P2O7, Ca(PO3)2, Ca10(PO4)6Cl2, etc. The preliminary calcination is carried out pref. in an atmosphere of <1Torr pressure, and the temp. for the preliminary calcination is pref. 100-1,400 deg.C. Obtd. material based on this calcium phosphate is used suitably for a filling material to be used in bones in dental surgery, orthopedic surgery, otolaryngology, etc.
Elevated concentrations of TNFα have been found in involved tissues and fluids of patients with RA, CD, UC, AS, PsA, and Ps. In RA, treatment with infliximab products reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion [E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)], chemoattraction [IL-8 and monocyte chemotactic protein (MCP-1)] and tissue degradation [matrix metalloproteinase (MMP) 1 and 3]. In CD, treatment with infliximab products reduced infiltration of inflammatory cells and TNFα production in inflamed areas of the intestine, and reduced the proportion of mononuclear cells from the lamina propria able to express TNFα and interferon. After treatment with infliximab products, patients with RA or CD exhibited decreased levels of serum IL-6 and C-reactive protein (CRP) compared to baseline. Peripheral blood lymphocytes from infliximab product-treated patients showed no significant decrease in number or in proliferative responses to in vitro mitogenic stimulation when compared to cells from untreated patients. In PsA, treatment with infliximab products resulted in a reduction in the number of T-cells and blood vessels in the synovium and psoriatic skin lesions as well as a reduction of macrophages in the synovium. In Ps, treatment with infliximab products may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which infliximab products exert their clinical effects is unknown.
FIELD: microbiology. SUBSTANCE: anthrax strain cultures are tested preliminary in vitro with respect to their capability to produce toxin in medium of capsule formation. Selected cultures at relative content of Tox + KOE 95-98% are subjected for selection on bilayer agar. Hemolysis zone-forming colonies (size is 2-8 mm) are isolated in 18-24 h. Selected cultures are tested and evaluated with respect to their culture-morpholigical properties, harmless and immunogenicity in vivo. Invention can be used for quality control of living anthrax vaccines. EFFECT: decreased time and cost for vaccine strains, subcultures and ready vaccines testing. 6 tbl, 6 ex
The cosmetic medium comprises alkyl or alkenyl oligoglycoside of general formula (I), partial glyceride and quaternary hydroxyethyl cellulose polymer. The quaternary hydroxyethyl cellulose polymer is cationically substituted with trimethyl ammonium group, and is modified with dimethyldodecylammonium group hydrophobically. Another cationic polymer, polyethylene glycol and a surfactant are also provided. The partial glyceride is oleic acid monoglyceride. The alkyl or alkenyl oligoglycoside having general formula (I). R1>O-[G]p R1>4-22C alkyl or alkenyl residue, preferably alkyl residue; G : 5 or 6C sugar residue; and p : 1-10. An independent claim is also included for a method for cleaning and caring skin and hair, which involves applying the medium on the skin or scalp.
The most frequent reactions are those affecting the nervous system and the liver.

Nervous System Reactions: Peripheral neuropathy is the most common toxic effect. It is dose- related, occurs most often in the malnourished and in those predisposed to neuritis (e.g., lcoholics and diabetics), and is usually preceded by paresthesias of the feet and hands. The incidence is higher in “slow inactivators.”

Other neurotoxic effects, which are uncommon with conventional doses, are convulsions, toxic encephalopathy, optic neuritis and atrophy, memory impairment, and toxic psychosis.

Hepatic Reactions: See boxed WARNING. Elevated serum transaminase (SGOT; SGPT), bilirubinemia, bilirubinuria, jaundice, and occasionally severe and sometimes fatal hepatitis. The common prodromal symptoms of hepatitis are anorexia, nausea, vomiting, fatigue, malaise, and weakness. Mild hepatic dysfunction, evidenced by mild and transient elevation of serum transaminase levels occurs in 10% to 20% of patients taking isoniazid. This abnormality usually appears in the first 1 to 3 months of treatment but can occur at any time during therapy. In most instances, enzyme levels return to normal, and generally, there is no necessity to discontinue medication during the period of mild serum transaminase elevation. In occasional instances, progressive liver damage occurs, with accompanying symptoms. If the SGOT value exceeds three to five times the upper limit of normal, discontinuation of the isoniazid should be strongly considered. The frequency of progressive liver damage increases with age. It is rare in persons under 20, but occurs in up to 2.3 percent of those over 50 years of age.

Gastrointestinal Reactions: Nausea, vomiting, and epigastric distress.

Hematologic Reactions: Agranulocytosis; hemolytic, sideroblastic, or aplastic anemia, thrombocytopenia; and eosinophilia.

Hypersensitivity Reactions: Fever, skin eruptions (morbilliform, maculopapular, purpuric, or exfoliative), lymphadenopathy, and vasculitis.

Metabolic and Endocrine Reactions: Pyridoxine deficiency, pellagra, hyperglycemia, metabolic acidosis, and gynecomastia.

Miscellaneous Reactions: Rheumatic syndrome and systemic lupus erythematosus-like syndrome.

To report SUSPECTED ADVERSE REACTIONS, contact West-ward Pharmaceutical Corp. at 1-877-233-2001, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Receives the Entrepreneurship School with Gender Lens intervention. Participants receive a general training with six modules focused on business modeling and female empowerment for the participants. It is targeted for women who are forcibly displaced people, including refugees, and who are survivors or at risk of Sexual or Gender Based Violence. Each women entrepreneur, participates in individual mentoring sessions to build their business plan after the training and receives $800 start-up capital for their business plan. For at least a year, entrepreneurs will have a follow-up to promote their business scale up, including how to formalize their business in the market, how to define new strategies, and how to answer to the market's evolving requirements. Additionally, the participants receive an extensive training in gender aspects that have been identified as relevant to promote women's empowerment. The intervention also includes mental health content.
<P>PROBLEM TO BE SOLVED: To provide an antibody which recognizes specifically the binding region of glycoproteins.  <P>SOLUTION: The immunogen is produced by digesting glycoproteins with protease without performing alkaline hydrolysis. An animal is immunized by the above immunogen, and an antibody-producing cell is collected from the animal. A monoclonal antibody is extracted from the antibody-producing cell or its hybridoma. The obtained antibody is applicable to various uses such as a recognition reagent for the binding region of glycoproteins, a recognition probe of tumor markers or a sugar-chain recognition probe, and has tremendous industrial availableness in various fields such as basic medical science, applied medical science or drug discovery.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:To obtain an excellent hair cosmetic by blending specific amounts of a mono- or di-long-chain alkyl quaternary ammonium salt type cationic surfactant with a cholesterol derivative and a specific dialkylene glycol monoalkyl ether. CONSTITUTION:The objective hair cosmetic is obtained by combining (A) 0.1-20.0wt.% mono- or di-long-chain alkyl quaternary ammonium salt type cationic surfactant with (B) 0.1-10.0wt.% cholesterol derivative (especially a cholesteryl ester of a branched fatty acid, etc.) and (C) 0.5-30.0wt.% dialkylene glycol monoalkyl ether of formula I (R1 is H or methyl; R<2> is 1-5C alkyl) (especially diethylene glycol monoethyl ether, etc.). A quaternary ammonium salt of formula II (at least one of R<3> to R<6> is alkyl, etc.; the rest are alkyl or hydroxyalkyl) is preferred as the surfactant. This hair cosmetic is capable of imparting good touch to the hair, preventing the hair from damaging and the scalp from whitening and exhibiting inhibiting effects on dandruff.
The mTOR pathway is commonly dysregulated in ER-positive breast cancers and represents a key resistance mechanism to endocrine therapy such as tamoxifen. We plan to target the mTOR pathway with mTORC1/2 inhibitor TAK-228 to overcome tamoxifen resistance in early-stage ER-positive breast cancer. An open label phase II clinical trial will be conducted to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer. TAK-228 (30 mg weekly) plus tamoxifen (20 mg daily) will be administered for 16 weeks. Patients will undergo tumor biopsy before starting the study treatment and after 6 weeks of study treatment. Blood samples for pharmacokinetics analysis will be obtained 1 hour before and after TAK-228 dosing on days 1 and 15 of the study.
The REACT trial has been designed as a feasibility study to investigate the impact of pre-, peri-, and postoperative computerized cognitive trainings on the incidence of postoperative cognitive dysfunction. Two different study groups (training programs) will be compared. Each group consists of two training modules of the validated computer based training program of cognitive functioning called RehaCom®. The experimental group consists of the modules 'Topological Memory (MEMO)' and 'Divided Attention 2 (GEA2)'. The active comparator group consists of the modules 'Topological Memory (MEMO)' and 'Working memory (WOME)'. 48 surgical patients undergoing elective urogynecological or breast cancer surgery will preoperatively be randomly assigned to one of two study groups. Before starting the training, patients will complete a neuropsychological test battery comprising the cognitive tests to measure POCD. The tests will be assessed at preoperative baseline visit and at 3-months follow-up. In order to correct change in cognitive performance for practice effects, a group of 24 female surgical control subjects will also prospectively be tested with the cognitive test battery at baseline and 3-months follow-up. The control subjects will be matched to the 2 study groups regarding health status, surgery and age, but will neither undergo the computerized cognitive training program RehaCom®. Further, 24 female control subjects are included from the POCD-Register (EA1/104/16) and will be matched to the 2 study groups as well.

After baseline assessment, the study group patients will be taught to use the training program RehaCom®, and training should start preoperatively as early as possible. The patients are recommended to perform the training daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.

The neuropsychological assessment will be performed at preoperative baseline and at three-months follow-up. Postoperative cognitive dysfunction (POCD) will be classified using the dichotomous approach established by Rasmussen et al in the International Study on postoperative cognitive deficits (ISPOCD) (Rasmussen et al. The assessment of postoperative cognitive function. Acta Anaesthesiol Scand. 2001 Mar;45(3):275-89.) This calculation method defines POCD as a reliable change in pre- and postoperative cognitive performance (difference scores) of each individual in the surgical patients cohort as compared to the changes in a non-surgical control group (reliable change index in either a composite score including cognitive test parameters from all tests in the cognitive test battery or in at least two of the chosen cognitive test parameters).

Secondary outcome measures of this trial comprise structural and functional MRI measures, Electroencephalogram simultaneous with fMRI, intraoperative cerebral oximetry and neuromonitoring, delirium, pain, sleep quality, postoperative complications, frailty, psychological distress, quality of life, training performance and evaluation of the training.
Inspiratory pressure will be adjusted to achieve an expired tidal volume of 7 ml/Kg; the respiratory rate will be adjusted to achieve an end ETCO2 at 32-35 mmHg, inspiratory to expiratory ratio at 1:2, PEEP at 4 cm H2O, and FiO2 at 0.5. No further adjustment in IP will be made throughout the surgery. LUS will be performed at the same fixed four-time interval as Group-B. Anesthesiologist will not do any interventions to the atelectatic areas in this group.
PURPOSE:To obtain an immunosuppression agent containing secretor IL-2 receptor as an active ingredient. CONSTITUTION:An immunosuppression agent containing secretor IL-2 receptor [a receptor having properties specifically combining with IL-2, soluble in an aqueous medium and having such properties as to be produced by a transformed strain and secreted into a culture medium when DNA sequence coding the IL-2 receptor is carried on a proper vector plasmid and introduced into a proper host in order to transform, e.g. a receptor having 40-43kd molecular weight, pI5.2-4.4 and the following amino acid sequence (N-terminated)] as an active ingredient. The agent is effective to remedy and prevention for an autoimmune disease, organ, rejection to bone marrow transplantation, etc., and can continuously be used without side effect. Intravenous injection is preferably used, though there are injection and drops in the formulation. The agent is preferably administered in an amount of 1-50ml/kg/day using the receptor having concentration of 5-250mg/ml.
NEW MATERIAL:4-Aminocotinine shown by the formula I. USE:White crystal, compound having 125-126 deg.C melting point, and specific rotary power [alpha]<25>d=-95.2 deg. (c=0.7, MeOH), useful as an improved artificial antigen for nicotine, having pyridine ring, pyrrolidine ring, and optical activity important as an artificial antigen for nicotine. PREPARATION:Cotinine shown by the formula II is oxidized with a preacid such as H2O2, etc. to form cotinine-N-oxide shown by the formula III, which is reacted with conc. sulfuric acid and fuming sulfuric acid to give 4- nitrocotinine-N-oxide shown by the formula IV. This compound is reduced with iron in acetic acid to give 4-aminocotinine shown by the formula V, which is reduced with diborane to give easily the compound shown by the formula I.
There is a lack of evidence that long-term opioid use offers benefit for noncancer pain and an abundance of evidence of harm. In 2017, the Centers for Disease Control and Prevention (CDC) issued the "CDC Guideline for Prescribing Opioids for Chronic Pain" to encourage safe and effective alternatives to opioids, discontinuation of opioids when patients do not resume normal activities and prudent dosing strategies. However, poor guideline adherence is a general concern and may impede uptake. Our prior studies have used insights from behavioral economics and social psychology to increase guideline adherence. The objective of the R21 pilot phase of the Application of Economics \& Social psychology to improve Opioid Prescribing Safety (AESOPS) is to develop and test novel behavioral nudges to encourage adherence to pain and CDC guidelines for opioid prescribing for persons with noncancer pain. At the time of opioid prescribing, clinicians will be prompted with an EHR nudge when the prescribing history for the patient falls into one of the following three mutually exclusive categories: Opioid naïve, At-risk for long term use, or Long-term opioid recipient. The primary outcome is average weekly morphine milligram equivalents (MME) prescribed per-clinician.
PURPOSE: A radioisotope-labeled folate-conjugated human serum albumin which is specific to tumor and lymph node is provided to reduced false negative possibility and to enhance biopsy accuracy of the lymph node. CONSTITUTION: A radioisotope-labeled folate-conjugated human serum albumin which is specific to tumor and sentinel lymph node is denoted by chemical formula 1, ((folate)_n-A-[S-R]_l). In chemical formula 1, A is disulfide reduction human serum albumin; S is sulfur; R is radioisotope, n is 1-21 integer, and l is 1-8 integer. The human serum albumin is conjugated with folate receptors of tumor. The radioisotope is [Tc-99m]Tc. The tumor expresses the folate receptor and includes breast cancer, kidney cancer, choroid plexus carcinoma, brain tumor, or lung cancer.
BACKGROUND: The current study mainly focused on provide further insights into the association of the miR-22-3p and miR-29c-3p expression in CFU-Hill colonies with birth weight and senescence process in children.
METHODS: This cross-sectional study evaluated 61 children (32 boys, 29 girls). The CFU-Hill colonies number was evaluated in vitro by cell culture technique and senescence was detected by β-galactosidase (SA-β-Gal) assay. Expression of miR-22-3p and miR-29c-3p isolated from CFU-Hill colonies were detected using quantitative real-time polymerase chain reaction.
RESULTS: Birth weight was correlated with both CFU-Hill colonies and %SA-β-Gal positive staining. Multivariate linear regression analysis revealed that the senescence was a predictor of the lower CFU-Hill colonies number, while only the birth weight was a predictor of senescence of CFU-Hill colonies. Overexpression of miR-22-3p and miR-29c-3p was observed in CFU-Hill colonies isolated from children with low birth weight (LBW). Interestingly, we found a significant correlation between %SA-β-Gal cells staining positive for both miR-22-3p and miR-29c-3p.
CONCLUSION: The LBW is associated with decreased CFU-Hill colonies number and high senescence of these cells. The overexpression of miR-22-3p and miR-29c-3p may be partially responsible for this alteration due to regulation of several pathways related to the senescence process.
IMPACT: The study establishes a significant correlation between birth weight and the number of CFU-Hill colonies, suggesting that birth weight could be a predictive biomarker for vascular health in children. Data indicates that cellular senescence is a predictor of reduced CFU-Hill colony numbers. This suggests that the aging process of these cells could be an important factor in understanding the vascular health issues in children with low birth weight. The overexpression of miR-22-3p and miR-29c-3p in children with low birth weight and their correlation with increased cellular senescence highlight these microRNAs as possible molecular mechanisms influencing the aging of CFU-Hill colonies.
BACKGROUND: Trauma is statistically a significant cause of mortality among patients across countries. Nevertheless, the precise correlation between genetic diagnostic markers and the intricate mechanism of trauma remains indistinct.
METHODS: Our study exclusively centered on trauma patients and selected three trauma-related datasets from the Gene Expression Omnibus (GEO) database, all of which had blood samples collected within post-traumatic 12 h. Differential gene screening, the WGCNA and Cytoscape software were employed to analyze the two datasets, with a particular emphasis on the top 100 genes selected based on MCC algorithm scores. A logistic diagnostic model was constructed by analyzing the intersection genes in the third dataset, leading to the identification of diagnostic biomarkers with high efficiency. The global immune landscape of these patients was extensively investigated using a multidimensional approach. Meanwhile, the underlying pathological and physiological mechanisms associated with early trauma status are summarized by integrating existing literature.
RESULTS: Out of these two GEO datasets, 21 overlapping genes were identified and incorporated into in the logistic diagnostic model constructed in the GSE36809 dataset. A panel of 9 genes was uncovered as a diagnostic biomarker, and their expression and correlation were subsequently verified. Additionally, by virtue of various algorithms, the findings revealed an upregulation of neutrophil expression and a downregulation of CD8+ T cell expression, indicating characteristic early trauma-induced inflammation activation and immune suppression. The correlation observed between the feature genes and immune cells serves to validate the exceptional diagnostic capability of these 9 genes in identifying trauma status and their promising potential for patients who could benefit from targeted immune interventions. Drawing from these findings, the discussion section offers insights into the underlying pathological and physiological mechanisms at play.
CONCLUSION: Our research has discovered a novel diagnostic biomarker and unveiled its association with post-traumatic immune alterations. This breakthrough enables accurate and timely diagnosis of early trauma, facilitating the implementation of appropriate healthcare interventions.